115 related articles for article (PubMed ID: 10937982)
1. Placebo-controlled comparison of candoxatril, an orally active neutral endopeptidase inhibitor, and captopril in patients with chronic heart failure.
Northridge DB; Currie PF; Newby DE; McMurray JJ; Ford M; Boon NA; Dargie HJ
Eur J Heart Fail; 1999 Mar; 1(1):67-72. PubMed ID: 10937982
[TBL] [Abstract][Full Text] [Related]
2. Candoxatril improves exercise capacity in patients with chronic heart failure receiving angiotensin converting enzyme inhibition.
Newby DE; McDonagh T; Currie PF; Northridge DB; Boon NA; Dargie HJ
Eur Heart J; 1998 Dec; 19(12):1808-13. PubMed ID: 9886723
[TBL] [Abstract][Full Text] [Related]
3. Comparison of the short-term effects of candoxatril, an orally active neutral endopeptidase inhibitor, and frusemide in the treatment of patients with chronic heart failure.
Northridge DB; Newby DE; Rooney E; Norrie J; Dargie HJ
Am Heart J; 1999 Dec; 138(6 Pt 1):1149-57. PubMed ID: 10577447
[TBL] [Abstract][Full Text] [Related]
4. Effects of renal neutral endopeptidase inhibition on sodium excretion, renal hemodynamics and neurohormonal activation in patients with congestive heart failure.
Kimmelstiel CD; Perrone R; Kilcoyne L; Souhrada J; Udelson J; Smith J; de Bold A; Griffith J; Konstam MA
Cardiology; 1996; 87(1):46-53. PubMed ID: 8631044
[TBL] [Abstract][Full Text] [Related]
5. Neutral endopeptidase versus angiotensin converting enzyme inhibition in essential hypertension.
Favrat B; Burnier M; Nussberger J; Lecomte JM; Brouard R; Waeber B; Brunner HR
J Hypertens; 1995 Jul; 13(7):797-804. PubMed ID: 7594444
[TBL] [Abstract][Full Text] [Related]
6. Neutral endopeptidase 24.11 inhibition may not exhibit beneficial haemodynamic effects in patients with congestive heart failure.
Kentsch M; Otter W; Drummer C; Nötges A; Gerzer R; Müller-Esch G
Eur J Clin Pharmacol; 1996; 51(3-4):269-72. PubMed ID: 9010697
[TBL] [Abstract][Full Text] [Related]
7. Hemodynamic and neuroendocrine effects for candoxatril and frusemide in mild stable chronic heart failure.
Westheim AS; Bostrøm P; Christensen CC; Parikka H; Rykke EO; Toivonen L
J Am Coll Cardiol; 1999 Nov; 34(6):1794-801. PubMed ID: 10577572
[TBL] [Abstract][Full Text] [Related]
8. Withdrawal of digoxin from patients with chronic heart failure treated with angiotensin-converting-enzyme inhibitors. RADIANCE Study.
Packer M; Gheorghiade M; Young JB; Costantini PJ; Adams KF; Cody RJ; Smith LK; Van Voorhees L; Gourley LA; Jolly MK
N Engl J Med; 1993 Jul; 329(1):1-7. PubMed ID: 8505940
[TBL] [Abstract][Full Text] [Related]
9. Effects of acetylsalicylic acid on peripheral hemodynamics in patients with chronic heart failure treated with angiotensin-converting enzyme inhibitors.
van Wijngaarden J; Smit AJ; de Graeff PA; van Gilst WH; van der Broek SA; van Veldhuisen DJ; Lie KI; Wesseling H
J Cardiovasc Pharmacol; 1994 Feb; 23(2):240-5. PubMed ID: 7511753
[TBL] [Abstract][Full Text] [Related]
10. The effect of the neutral endopeptidase inhibitor drug, candoxatril, on circulating levels of two of the most potent vasoactive peptides.
McDowell G; Coutie W; Shaw C; Buchanan KD; Struthers AD; Nicholls DP
Br J Clin Pharmacol; 1997 Mar; 43(3):329-32. PubMed ID: 9088591
[TBL] [Abstract][Full Text] [Related]
11. Angiotensin II receptor antagonists and heart failure: angiotensin-converting-enzyme inhibitors remain the first-line option.
Prescrire Int; 2005 Oct; 14(79):180-6. PubMed ID: 16285075
[TBL] [Abstract][Full Text] [Related]
12. Candoxatril, a neutral endopeptidase inhibitor: efficacy and tolerability in essential hypertension.
Bevan EG; Connell JM; Doyle J; Carmichael HA; Davies DL; Lorimer AR; McInnes GT
J Hypertens; 1992 Jul; 10(7):607-13. PubMed ID: 1321186
[TBL] [Abstract][Full Text] [Related]
13. [Effect of captopril on the exercise performance in patients with congestive heart failure].
Han YL; Tong M; Miao ZL
Zhonghua Nei Ke Za Zhi; 1992 May; 31(5):281-3, 317. PubMed ID: 1478125
[TBL] [Abstract][Full Text] [Related]
14. Omapatrilat, a dual angiotensin-converting enzyme and neutral endopeptidase inhibitor, prevents fatty streak deposit in apolipoprotein E-deficient mice.
Arnal JF; Castano C; Maupas E; Mugniot A; Darblade B; Gourdy P; Michel JB; Bayard F
Atherosclerosis; 2001 Apr; 155(2):291-5. PubMed ID: 11254898
[TBL] [Abstract][Full Text] [Related]
15. [Effectiveness and tolerance of benazepril versus captopril in patients with hypertension].
Ol'binskaia LI; Golubev SA; Morozova TE
Klin Med (Mosk); 1995; 73(5):36-8. PubMed ID: 8815273
[TBL] [Abstract][Full Text] [Related]
16. [Acetylsalicylic acid antagonism vs ACE inhibitor in congestive heart failure as shown by a diminished respiratory and exercise capacity].
Guazzi M; Lauri G; Melzi G; Cattadori G; Agostoni P
Cardiologia; 1996 Jun; 41(6):527-33. PubMed ID: 8766415
[TBL] [Abstract][Full Text] [Related]
17. [Effectiveness of long-term ACE-inhibition on pulmonary diffusion and ventilation-perfusion ratio in chronic heart failure: correlation with physical performance].
Guazzi M; Pontone G; Trevisi N; Lomanto M; Melzi G; Agostoni P
Ann Ital Med Int; 1998; 13(1):17-23. PubMed ID: 9642838
[TBL] [Abstract][Full Text] [Related]
18. Candoxatril, an orally active neutral endopeptidase inhibitor, raises plasma atrial natriuretic factor and is natriuretic in essential hypertension.
O'Connell JE; Jardine AG; Davidson G; Connell JM
J Hypertens; 1992 Mar; 10(3):271-7. PubMed ID: 1315825
[TBL] [Abstract][Full Text] [Related]
19. [A case of severe heart failure complicating chronic hemodialysis in which angiotensin converting enzyme inhibitor was markedly effective].
Nomura S; Takagi N; Oda H; Ikeda Y; Yoshimura H; Kimura K; Minamisawa K; Shionoiri H; Kaneko Y; Onishi T
Nihon Jinzo Gakkai Shi; 1987 Oct; 29(10):1281-6. PubMed ID: 2831419
[No Abstract] [Full Text] [Related]
20. Effectiveness of endopeptidase inhibition (candoxatril) in congestive heart failure.
Elsner D; Müntze A; Kromer EP; Riegger GA
Am J Cardiol; 1992 Aug; 70(4):494-8. PubMed ID: 1386491
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
